160 related articles for article (PubMed ID: 35702037)
1. The pharmacotherapeutic management of nail unit and acral melanomas.
Falotico JM; Lipner SR
Expert Opin Pharmacother; 2022 Aug; 23(11):1273-1289. PubMed ID: 35702037
[TBL] [Abstract][Full Text] [Related]
2. Metastatic acral melanoma treatment outcomes: a systematic review and meta-analysis.
Cho KK; Cust AE; Foo YM; Long GV; Menzies AM; Eslick GD
Melanoma Res; 2021 Oct; 31(5):482-486. PubMed ID: 34433196
[TBL] [Abstract][Full Text] [Related]
3. Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy.
Li J; Smalley I; Chen Z; Wu JY; Phadke MS; Teer JK; Nguyen T; Karreth FA; Koomen JM; Sarnaik AA; Zager JS; Khushalani NI; Tarhini AA; Sondak VK; Rodriguez PC; Messina JL; Chen YA; Smalley KSM
Clin Cancer Res; 2022 May; 28(10):2131-2146. PubMed ID: 35247927
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy in Acral and Mucosal Melanoma: Current Status and Future Directions.
Mao L; Qi Z; Zhang L; Guo J; Si L
Front Immunol; 2021; 12():680407. PubMed ID: 34149718
[TBL] [Abstract][Full Text] [Related]
5. Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients.
Tang B; Yan X; Sheng X; Si L; Cui C; Kong Y; Mao L; Lian B; Bai X; Wang X; Li S; Zhou L; Yu J; Dai J; Wang K; Hu J; Dong L; Song H; Wu H; Feng H; Yao S; Chi Z; Guo J
J Hematol Oncol; 2019 Jan; 12(1):7. PubMed ID: 30642373
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of nab-paclitaxel combined with carboplatin in Chinese patients with melanoma.
Guo YQ; Ding Y; Li DD; Li JJ; Peng RQ; Wen XZ; Zhang X; Zhang XS
Med Oncol; 2015 Sep; 32(9):234. PubMed ID: 26298530
[TBL] [Abstract][Full Text] [Related]
7. Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy.
Kong Y; Sheng X; Wu X; Yan J; Ma M; Yu J; Si L; Chi Z; Cui C; Dai J; Li Y; Yu H; Xu T; Tang H; Tang B; Mao L; Lian B; Wang X; Yan X; Li S; Guo J
Clin Cancer Res; 2017 Nov; 23(22):6946-6957. PubMed ID: 28830923
[No Abstract] [Full Text] [Related]
8. Cross-sectional study of acral melanoma awareness in a group of South African final phase medical students.
Eksteen JM; Visser WI; de Wet J; Lombard C; Zunza M; Tod B
Indian J Dermatol Venereol Leprol; 2022; 88(3):444. PubMed ID: 35389032
[TBL] [Abstract][Full Text] [Related]
9. Targeted Genomic Profiling of Acral Melanoma.
Yeh I; Jorgenson E; Shen L; Xu M; North JP; Shain AH; Reuss D; Wu H; Robinson WA; Olshen A; von Deimling A; Kwok PY; Bastian BC; Asgari MM
J Natl Cancer Inst; 2019 Oct; 111(10):1068-1077. PubMed ID: 30657954
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant PD-1 inhibitor versus high-dose interferon α-2b for Chinese patients with cutaneous and acral melanoma: A retrospective cohort analysis.
Li J; Wang J; Li D; Wen X; Ding Y; Liu X; Jiang H; Huang F; Zhang X
Dermatol Ther; 2021 Sep; 34(5):e15067. PubMed ID: 34302318
[TBL] [Abstract][Full Text] [Related]
11. BRAF inhibitors: efficacious and tolerable in BRAF-mutant acral and mucosal melanoma.
Bai X; Mao LL; Chi ZH; Sheng XN; Cui CL; Kong Y; Dai J; Wang X; Li SM; Tang BX; Lian B; Zhou L; Yan XQ; Guo J; Si L
Neoplasma; 2017; 64(4):626-632. PubMed ID: 28485171
[TBL] [Abstract][Full Text] [Related]
12. Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patients.
Nakamura Y; Namikawa K; Yoshino K; Yoshikawa S; Uchi H; Goto K; Nakamura Y; Fukushima S; Kiniwa Y; Takenouchi T; Uhara H; Kawai T; Hatta N; Funakoshi T; Teramoto Y; Otsuka A; Doi H; Ogata D; Matsushita S; Isei T; Hayashi T; Shibayama Y; Yamazaki N
Ann Oncol; 2020 Sep; 31(9):1198-1206. PubMed ID: 32522691
[TBL] [Abstract][Full Text] [Related]
13. Nail Apparatus Melanoma: Current Management and Future Perspectives.
Ito T; Hashimoto H; Kaku-Ito Y; Tanaka Y; Nakahara T
J Clin Med; 2023 Mar; 12(6):. PubMed ID: 36983205
[TBL] [Abstract][Full Text] [Related]
14. Acral melanoma: new insights into the immune and genomic landscape.
Carvalho LAD; Aguiar FC; Smalley KSM; Possik PA
Neoplasia; 2023 Dec; 46():100947. PubMed ID: 37913653
[TBL] [Abstract][Full Text] [Related]
15. Management of Acral and Mucosal Melanoma: Medical Oncology Perspective.
Jung S; Johnson DB
Oncologist; 2022 Aug; 27(8):703-710. PubMed ID: 35640549
[TBL] [Abstract][Full Text] [Related]
16. Toripalimab for the treatment of melanoma.
Tang B; Chi Z; Guo J
Expert Opin Biol Ther; 2020 Aug; 20(8):863-869. PubMed ID: 32406293
[TBL] [Abstract][Full Text] [Related]
17. Intralesional and systemic immunotherapy for metastatic melanoma.
Luu C; Khushalani NI; Zager JS
Expert Opin Biol Ther; 2016 Dec; 16(12):1491-1499. PubMed ID: 27602429
[TBL] [Abstract][Full Text] [Related]
18. Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry.
Cho J; Ahn S; Yoo KH; Kim JH; Choi SH; Jang KT; Lee J
Invest New Drugs; 2016 Dec; 34(6):677-684. PubMed ID: 27491654
[TBL] [Abstract][Full Text] [Related]
19. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
20. Biological behavior and natural course of acral malignant melanoma. Clinical and histologic features and prognosis of palmoplantar, subungual, and other acral malignant melanomas.
Jimbow K; Takahashi H; Miura S; Ikeda S; Kukita A
Am J Dermatopathol; 1984; 6 Suppl():43-53. PubMed ID: 6528942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
